Difficulty: Medium
Average Score: 76%
Practice
The following is NOT a characteristic feature of rivaroxiban compared to warfarin:
Correct answer
D
Rationale
In this question, the correct answer is D) It can be safely given in renal impairment.
Rivaroxaban is a direct factor Xa inhibitor, while warfarin is a vitamin K antagonist. Rivaroxaban is primarily eliminated by the liver, unlike warfarin which is metabolized in the liver and excreted by the kidneys. This key difference means that rivaroxaban is a preferred choice in patients with renal impairment, as its efficacy and safety are not significantly affected by impaired kidney function.
Now, let's discuss why the other options are incorrect:
A) Rivaroxaban actually has a relatively rapid onset of action, with peak plasma concentrations achieved around 2-4 hours after administration, not 30 minutes.
B) Unlike warfarin which requires regular monitoring of INR levels to ensure therapeutic efficacy and prevent adverse effects, rivaroxaban does not require routine INR monitoring due to its predictable pharmacokinetics.
C) Rivaroxaban has fewer drug interactions compared to warfarin, especially with CYP450 interacting drugs, making it a more convenient option in terms of managing potential drug interactions.
In an educational context, understanding the differences between rivaroxaban and warfarin is crucial for healthcare professionals involved in the management of patients requiring anticoagulation therapy. Knowledge of these distinctions ensures appropriate selection of anticoagulants based on individual patient characteristics, ultimately leading to improved patient outcomes and safety.
Rivaroxaban is a direct factor Xa inhibitor, while warfarin is a vitamin K antagonist. Rivaroxaban is primarily eliminated by the liver, unlike warfarin which is metabolized in the liver and excreted by the kidneys. This key difference means that rivaroxaban is a preferred choice in patients with renal impairment, as its efficacy and safety are not significantly affected by impaired kidney function.
Now, let's discuss why the other options are incorrect:
A) Rivaroxaban actually has a relatively rapid onset of action, with peak plasma concentrations achieved around 2-4 hours after administration, not 30 minutes.
B) Unlike warfarin which requires regular monitoring of INR levels to ensure therapeutic efficacy and prevent adverse effects, rivaroxaban does not require routine INR monitoring due to its predictable pharmacokinetics.
C) Rivaroxaban has fewer drug interactions compared to warfarin, especially with CYP450 interacting drugs, making it a more convenient option in terms of managing potential drug interactions.
In an educational context, understanding the differences between rivaroxaban and warfarin is crucial for healthcare professionals involved in the management of patients requiring anticoagulation therapy. Knowledge of these distinctions ensures appropriate selection of anticoagulants based on individual patient characteristics, ultimately leading to improved patient outcomes and safety.